Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its peers? We will compare Synaptogenix to related businesses based on the strength of its earnings, dividends, institutional ownership, valuation, risk, profitability and analyst recommendations.

Valuation and Earnings

This table compares Synaptogenix and its peers gross revenue, earnings per share (EPS) and valuation.

Synaptogenix's peers have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Institutional & Insider Ownership

9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Synaptogenix and its peers' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Synaptogenix and its peers, as provided by MarketBeat.

Synaptogenix currently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher probable upside, equities analysts clearly believe Synaptogenix is more favorable than its peers.

Summary

Synaptogenix peers beat Synaptogenix on 7 of the 13 factors compared.

About Synaptogenix

(Get Rating)

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.